Companies To Watch

  1. Companies To Watch: Synspira

    Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”

  2. Companies To Watch: Athersys

    Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.

  3. Companies To Watch: Symbiotix Biotherapies

    Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical-stage development of its lead compound for treating MS and IBD.

  4. Companies To Watch: United Neuroscience

    “We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”

  5. Companies To Watch: Acceleron

    Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).

  6. Companies To Watch: Sensorion

    This French company is addressing vertigo and hearing loss inside the inner ear.

  7. Companies To Watch: Landos Biopharma

    Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.

  8. Companies To Watch: CytoDyn

    CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.

  9. Companies To Watch: AmpliPhi Biosciences

    AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

  10. Companies To Watch Roundup 2017

    We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.